Press Archive
- Charles Francis: Weakening eye surgery laws places WV patients in jeopardy
- Mark D. Mayle, MD - 2022 Secretariat Award Recipients
- Dr. Larry Schwab recognized with 2020 International Blindness Prevention Award
- Wow Moment with Joseph A. LoCasio | Bio-Tissue | #WowWednesdays
- WVU Today | Moore, Oppe named recipients of Heebink award for Distinguished Service
- Cornea Transplant Restores Young Boy’s Sight After Fishing Accident
- Keep your eyes healthy and safe in the workplace
- Glaucoma Awareness Month
- Ophthalmologists Say 90 Percent of Work-Related Eye Injuries Can be Avoided by Wearing Eye Protection
- Five Tips to Avoid Toy-Related Eye Injuries
- Details
Parsa and Hoyt1 in their editorial state that nonarteritic anterior ischemic optic neuropathy (NAION) is not ischemic in nature, but is primarily owing to vitreous traction of the optic disc. They go on to state, “What is the evidence for ischemia in this entity?”
- Details
Joachim et al (p. 2482) evaluated the incidence and progression of age-related macular degeneration (AMD) over a 15-year period in 3654 adults who were 49 years of age or older and participating in the Blue Mountain Eye Study. The researchers found an overall incidence of 22.7% for early AMD and 6.8% for late AMD. After adjusting for competing risks, the incidence of early and late AMD was 15.1% and 4.1%, respectively; after further age standardization to the Beaver Dam Eye Study population, early and late incidence was 13.1% and 3.3%, respectively.
- Details
A 69-year-old man with vitreomacular adhesion of an epiretinal membrane without foveal traction in the right eye. The images are en-face optical coherence tomography with 3-dimensional reconstruction (top) and a vertical cross-sectional B-scan of the fovea showing a unique “vortex” formation (bottom).
Read more: Vitreous Vortex: A Unique Case of Vitreomacular Adhesion
- Details
Joachim y otros (p. 2482) evaluaron la incidencia y progresión de la degeneración macular relacionada con la edad (AMD) durante un período de 15 años en 3.654 adultos de 49 años o más que participaron en el Estudio Oftalmológico Blue Mountain (Blue Mountain Eye Study). Los investigadores encontraron una incidencia global de 22,7% para AMD temprana y 6,8% para AMD tardía. Después de hacer los ajustes para riesgos competitivos, la incidencia de AMD temprana y tardía fue de 15,1% y 4,1%, respectivamente; después de una mayor estandarización de edades con la población del Estudio Oftalmológico Beaver Dam (Beaver Dam Eye Study), la incidencia temprana y tardía fue de 13,1% y 3,3%, respectivamente.